obJeCtive Patients with poor-grade aneurysmal subarachnoid hemorrhage (aSAH) (World Federation of Neurosurgical Societies Grade IV or V) are often considered for decompressive craniectomy (DC) as a rescue therapy for refractory intracranial hypertension. The authors performed a systematic review and meta-analysis to assess the impact of DC on functional outcome and death in patients after poor-grade aSAH. MethoDs A systematic review and meta-analysis were performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Articles were identified through the Ovid Medline, Embase, Web of Science, and Cochrane Library databases from inception to October 2015. Only studies dedicated to patients with poor-grade aSAH were included. Primary outcomes were death and functional outcome assessed at any time period. Patients were grouped as having a favorable outcome (modified Rankin Scale [mRS] Scores 1-3, Glasgow Outcome Scale [GOS] Scores 4 and 5, extended Glasgow Outcome Scale [GOSE] Scores 5-8) or unfavorable outcome (mRS Scores 4-6, GOS Scores 1-3, GOSE Scores 1-4). Pooled estimates of event rates and odds ratios with 95% confidence intervals were calculated using the random-effects model. resuLts Fifteen studies encompassing 407 patients were included in the meta-analysis (all observational cohorts). The pooled event rate for poor outcome across all studies was 61.2% (95% CI 52%-69%) and for death was 27.8% (95% CI 21%-35%) at a median of 12 months after aSAH. Primary (or early) DC resulted in a lower overall event rate for unfavorable outcome than secondary (or delayed) DC (47.5% [95% CI 31%-64%] vs 74.4% [95% CI 43%-91%], respectively). Among studies with comparison groups, there was a trend toward a reduced mortality rate 1-3 months after discharge among patients who did not undergo DC ]; p = 0.168). However, this trend was not sustained at the 1-year follow-up (OR 1.09 [95% CI 0.55-2.13]; p = 0.79).
A NEURYSMAL subarachnoid hemorrhage (aSAH) is associated with high rates of disability and death; the overall mortality rate has reached 40% in some centers. 3, 8, 29 Established predictors of unfavorable outcome after aSAH 22 include poor clinical grade (defined as a Hunt and Hess [H&H] 23 or World Federation of Neurosurgical Societies [WFNS] 43 grade of IV or V or VASOGRADE-Red), 11, 12 elevated intracranial pressure (ICP) during hospital admission, aneurysmal rebleeding, and delayed cerebral ischemia.
Decompressive craniectomy (DC) is often used as a rescue therapy for refractory elevated ICP or malignant edema, largely in the context of traumatic brain injury (TBI) or ischemic infarction. 20 The effect of DC on survival after aSAH was evaluated recently in multiple studies, which typically focused on patients with a poor clinical grade, who are more likely to undergo DC than those with a good clinical grade. 14, 24, 34, 40, 45 Results of these studies were mixed, including support and disagreement regarding the use of DC, and the evidence from each of these publications is not sufficient to guide clinical decision making for the use of DC in patients with aSAH. Therefore, the purpose of this systematic review and meta-analysis was to investigate the effect of DC on functional outcome and death in patients with a poor clinical grade after aSAH.
Methods

Protocol
The search protocol, including research questions and inclusion and exclusion criteria, was developed a priori according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 31 guidelines.
search strategy A literature search was performed using relevant key words to identify cases of aSAH that required DC. Articles were identified by searching the Ovid Medline, Embase, Web of Science, and Cochrane Library databases from inception to October 2015 (Supplemental Tables 1-4 ). The references of included publications were searched manually for other relevant papers. The following key words were used in combination: "decompressive," "craniectomy," "hemicraniectomy," "aneurysmal," "aneurysm," "subarachnoid hemorrhage," and "rupture." Our search was limited to articles in English. There were no restrictions on publication type or dates.
eligibility Criteria
We included in our analyses studies that were randomized and had an observational prospective or retrospective study design; studies that were dedicated to patients with poor-grade aSAH (WFNS or H&H Grade IV or V) or in which at least 80% of the participants had poor-grade aSAH; and studies that reported functional outcomes using the modified Rankin scale (mRS), 4 the Glasgow Outcome Scale (GOS), 48 or the extended Glasgow Outcome Scale (GOSE) 48 at any time period. Excluded from the study were single case reports and reviews, non-peer-reviewed conference abstracts and reports, and animal studies.
study eligibility
Two reviewers (N.M.A. and G.A.E.) independently and in duplicate performed title and abstract screening from the search query results. The full texts of eligible studies were obtained; the reviewers solved all disagreements through discussion or consultation with a third reviewer (D.G.) when needed. We maintained a full list of excluded articles along with reasons for their exclusion.
outcomes and Measures
The primary outcomes of interest were functional outcome and death after DC. The metric of functional outcome was the mRS, GOS, or GOSE. Because of disparities in outcome and follow-up reporting among the studies, we dichotomized functional outcome as favorable (mRS Scores 1-3, GOS Scores 4 and 5, GOSE Scores 5-8) or unfavorable (mRS Scores 4-6, GOS Scores 1-3, GOSE Scores 1-4). For comparison in the meta-analysis, outcomes were categorized as early (outcome score at hospital discharge or 1 or 3 months after aSAH) or late (outcome score at 6 months or 1 year after aSAH). Secondary outcomes among eligible studies included causes of refractory intracranial hypertension and predictors of poor outcome.
Data extraction
The following data were extracted from each study by 2 of the authors (N.M.A. and G.A.E.) independently: study design, patient eligibility criteria, duration of follow-up and time at which follow-up was performed, sex and age of the patients, WFNS, H&H, and Fisher grades, 15 time to surgery, functional outcome scores, and mortality rate. The reviewers resolved all disagreements through discussion. The causes of high ICP in patients with aSAH were categorized based on timing (i.e., primary or secondary) and pathology (i.e., presence [and cause] or absence of mass effect), as suggested by Güresir et al. 17 The definition for each category is shown in Table 1 .
evaluation of Quality and risk-of-bias assessment for individual studies
The quality of all eligible studies was evaluated independently and in duplicate by 2 of the authors (N.M.A. and G.A.E.) using the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence. 49 One reviewer (N.M.A.) evaluated each study independently for risk of bias using the following 7 criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Each criterion was rated as having a high, unclear, or low risk of bias. Final judgments regarding risk of bias were made using an a priori custom-made guide that we developed (Supplemental Table 5 ).
statistical analysis
Pooled estimates and event rates with 95% CIs from all studies were combined using a random-effects model (DerSimonian-Laird). 13 Statistical comparisons were performed only for studies that contained matched control groups. For each outcome, odds ratios and 95% CIs were calculated. The Z-test was used to determine the significance of pooled odds ratios. We considered p values of less than 0.05 to be significant. All statistical analyses were performed using Review Manager Software (RevMan Version 5.3 [Nordic Cochrane Centre, The Cochrane Collaboration]) and a comprehensive meta-analysis software suite (BioStat, Inc.).
assessment of Publication bias and heterogeneity across studies
Publication bias was evaluated by visual evaluation of funnel plots and use of the Egger regression asymmetry test. The chi-square-based Q test and the I 2 test were used to assess heterogeneity between the studies. A p value of ≤ 0.05 and an I 2 value of > 40% were set to indicate heterogeneity between studies included for analysis.
results search results
The number of articles retained at each stage of data acquisition is shown in a PRISMA flow chart (Fig. 1) . Title and abstract screening by our 2 reviewers led to full-text reviews of 28 articles. Further screening of the potentially eligible articles through full-text examination resulted in the exclusion of 13 articles, which left only 15 of the remaining articles selected for analysis. Complete descriptions of the search results and excluded citations after full-text review (with justifications) are provided in Supplemental Tables 1-4 .
study Characteristics
Detailed study parameters and summary statistics from all included studies (with and without a matched control group) that investigated DC in patients with poor-grade aSAH are listed in Tables 2 and 3 (5), and Asia (8) . The sample sizes of patients who underwent DC ranged from 6 to 70. Regarding time of surgery, the majority of studies reported primary DC only (7 studies), followed by reports of both primary and secondary DC (5 studies). The most common pathology for high ICP that necessitated DC was presence of mass effect secondary to initial rupture (Category A, 10 studies), followed by global edema and intraoperative swelling (Category B, 3 studies) and cerebral infarction caused by vasospasm (Category C, 3 studies) (see Table 1 for definitions). In 9 studies, the last follow-up was 1 year after treatment (range was time of discharge to 6 years after treatment).
risk of bias in individual studies and evaluation of study Quality
The risk-of-bias assessment of included articles is shown in Supplemental Figs. 1 and 2. All studies were at high risk for selection bias, and they all were classified as having an OCEBM Level 4 evidence grade.
results of individual studies and synthesis of results
Overall Effect on Functional Outcomes
Using outcomes reported for 407 patients at last follow-up (median 12 months), the distribution of effect sizes across all studies is shown in Fig. 2 . Pooled event rates across all studies were 61.2% (95% CI 52.0%-69.7%) for poor outcome and 27.8% (95% CI 21.3%-35.5%) for death. The degree of heterogeneity for both outcome variables was significant (p < 0.05, chi-square-based Q test; I 2 test > 40%).
Patients Who Underwent DC Versus Matched Controls
The proportions of patients with poor neurological outcome in the 3 studies with matched controls included in the meta-analysis were reported for early (1-to 3-month) and late (12-month) follow-up (Fig. 3) . The likelihood of a poor outcome was not significantly different among patients who underwent DC relative from that of the matched controls at early follow-up (OR or combination of any of them) ICH = intracerebral hemorrhage; IVH = intraventricular hemorrhage; SDH = subdural hematoma. Based on data from Güresir et al. 17 with modification.
n. M. alotaibi et al.
J neurosurg January 6, 2017 4 p = 0.168). However, the trend was not sustained 1 year after discharge (OR 1.09 [95% CI 0.55-2.13]; p = 0.79). Heterogeneity between these studies was not significant.
Sensitivity Analysis
Because of the high incidence of poor outcomes in the primary analysis, a sensitivity analysis was conducted to determine the putative effects of the timing of DC and the reported follow-up times on the outcome measures ( . Heterogeneity values among the primary DC cohorts were not significant and were all lower than the overall pooled event rate for both the early and late follow-up periods.
Predictors of Outcomes After DC
Clinically, anisocoria and high WFNS grade (WFNS Grade V relative to Grade IV) at presentation were significantly associated with poor outcome. 21, 35, 45, 47 In 1 study, a favorable outcome was more likely in younger patients (< 60 years old). 27 The severity of midline shift, volume of hematoma measured by CT, and delayed surgical treatment were all significantly associated with unfavorable outcome. 7, 27, 35, 44, 47 Patients who underwent early or primary DC (at aSAH initial presentation) required a shorter duration of mechanical ventilation and overall shorter hospital stays than those who underwent late or secondary DC (mean ± SD 14.4 ± 3.3 vs 25.5 ± 3.4 days, respectively). 26 One study compared outcomes between patients who underwent clipping with simultaneous decompression surgery and those who underwent coil embolization followed by decompression; significantly better outcomes were found at discharge in the latter group. 24 Kazumata et al. 27 noted that hematoma location could influence out- comes because poorer outcome was found in patients with sylvian hematoma than in those with frontal hematoma.
Assessment of Publication Bias
Publication bias was assessed by using funnel plots and formal statistical analyses (Supplemental Fig. 3 ). Modest asymmetry can be seen in the funnel plots for both outcome measures, which might suggest reporting bias in cohorts with high rates of poor clinical outcome and death. However, statistical measures of publication bias determined by the Begg-Mazumdar and Egger scores were not significant.
Discussion
There are several findings from this study. Overall, DC is associated with high event rates of unfavorable outcome in patients with poor-grade aSAH. In 11 of 15 studies included in our analysis, ≥ 50% of patients who underwent DC had an unfavorable outcome (mRS Scores 4-6, GOS Scores 1-3, GOSE Scores 1-4) at their last follow-up. The evidence for the use of DC versus other interventions to treat high ICP is still unclear. Primary DC might be superior to secondary DC for reducing poor-outcome rates (47% vs 74%, respectively). Last, significant heterogeneity among DC studies for aSAH was found.
Functional outcomes and Death
Clinical grade is thought to be the most significant predictor of outcome after aSAH. 18 Elevated ICP is also a known negative predictor of outcome. 2, 30, 32 In patients with mass effect, DC has been shown to improve survival and functional outcome after a malignant infarction. 20, 36 For this reason, authors of previous studies have advocated for DC in patients with aSAH because, theoretically, it has an effect on ICP management that is comparable to that after a malignant infarction and can lead to better outcome. 36 Improvement in aerobic glucose utilization and reduction in cellular stress were observed after DC in patients with aSAH and high ICP; however, this result was seen in a retrospective study. 33 In in vivo studies with animal models of aSAH, DC did not result in any improvement in neurological outcomes or death. 6 Improvements in aneurysm protection and management of related complications in recent decades have translated into a considerably reduced mortality rate in patients with aSAH. However, despite these advances, fatality rates for patients with aSAH remain as high as 40%. 8 The pooled rates from our study are consistent with those in recent reports from investigations of functional outcome in patients with poor-grade aSAH, which estimated that up to 50% of patients with poor-grade aSAH experience devastating neurological deficits or death.
5,42,50,51
There is no pathology similar to aSAH that can produce brain injury with early and further delayed harmful effects. Compared with results from a similar cohort of patients with diffuse brain injury and poor preoperative clinical status in the DECRA (Decompressive Craniectomy in Patients With Severe Traumatic Brain Injury) randomized trial, 9 the proportion of patients with an unfavorable outcome (GOSE Scores 1-4) at the 6-month follow-up was 70%, which is higher than our overall event rate at late follow-up (58% [95% CI 31%-64%]). In contrast, the reported mortality rate for the DC group in the DECRA study was 19%; our mortality rate at late follow-up was 29% (95% CI 20%-39% revealed that the proportion of patients with an unfavorable outcome (defined as mRS Scores 4-6) at the 12-month follow-up was 57%, which is similar to our overall event rate at late follow-up (58% [95% CI 31%-64%]). These differences and similarities highlight the obscurity and uncertainty of obtaining clinical evidence for DC from other pathologies and applying this treatment in patients with aSAH.
DC versus nonsurgical therapy for high iCP
The use of medical approaches such as administering mannitol, hypertonic saline, and barbiturates in patients with aSAH and high ICP remains controversial. 11 Many neurosurgical centers tailor their high-ICP protocols for patients with aSAH to mirror those found in the literature for TBI. 11 Part of the challenge in determining whether DC has an effect on outcomes that is superior to that of medical treatment is the lack of robust control groups in the majority of studies that have investigated DC for treating aSAH. In our analysis, we were not able to demonstrate a relative benefit in either treatment arm for high ICP in patients with poor-grade aSAH. Although DC seemed to improve early mortality rates, statistical significance was not achieved. This finding might be related to the immediate effect of DC in reducing ICP and preventing death as a result of herniation. A number of possible causes could explain why patients who had better early survival after DC ultimately had the same unfavorable outcome as patients who did not undergo DC. For example, these patients might have experienced complications secondary to immobility or the natural post-aSAH disease course. Furthermore, the treatment modality used to repair a ruptured aneurysm might be an important consideration when considering DC for patients with poor-grade aSAH; 1 previous study found that decompression after endovascular coiling, rather than neurosurgical clipping, led to better patient outcomes, 24 which might have been related to perioperative complications at the time of aneurysm repair.
timing of surgery
It is well recognized that the timing of DC might play a role in improving outcomes. The Hemicraniectomy After Middle Cerebral Artery Infarction With Life-Threatening Edema Trial (HAMLET) found that surgery within 48 hours of stroke onset significantly reduced the probability of severe disability or death, whereas delayed DC (96 hours after stroke) did not influence outcome. 20 This effect was also observed in our sensitivity analysis, which revealed that primary DC might be more effective in reducing unfavorable-outcome rates than secondary DC. Earlier decompression can decrease the likelihood of additional brain injury by reducing the time of exposure to high ICP secondary to hematoma-or infarction-induced brain edema. 41 However, on the basis of evidence seen in ischemic stroke studies, this beneficial effect of early DC might be limited to patients with aSAH and a unilateral pathology (hematoma or infarction).
heterogeneity among DC studies
Our study identified significant heterogeneity among studies of DC for treating aSAH. Pertinent issues in reporting DC results in patients with aSAH identified in the eligible studies in our analysis include inconsistencies with the outcome scales used and differences in follow-up times across studies. In addition, it is important to consider that increased ICP in the setting of aSAH can occur as a result of numerous intracranial pathologies, including but not limited to diffuse edema, extraaxial or intraaxial hematoma, and infarct. 19 The lack of subgroup analysis for etiologies of high ICP is another potential factor for this interstudy heterogeneity. Last, because the majority of studies that investigated DC for the treatment of aSAH were retrospective, hidden bias challenges the validity of the findings in these reports.
strengths and Limitations
Ours is the first systematic review of DC for the treatment of aSAH that highlights our current progress in understanding the role of this surgical procedure among patients with poor-grade aSAH. The primary limitation of our study was the relatively small number of studies included in the meta-analysis; therefore, this analysis might not have been sufficiently powered to detect small effect sizes. Moreover, the studies included were based on small patient sample sizes. It is important to note that the absence of robust control groups in a majority of the studies evaluated limits the applicability of our findings. Last, although the search strategy was used systematically by 2 independent reviewers, it might have been limited by our choice of search terms and by selecting only English-language publications and therefore, as with any meta-analysis, might not be exhaustive.
assessment of Confounders
Different etiologies of high ICP in patients with aSAH are the main confounder among the studies. We were unable to develop a pooled subgroup analysis because of the heterogeneity of the studies and deficiency in reporting this variable.
implications for Clinical Practice
Surgical management of refractory intracranial hypertension in patients with poor-grade aSAH using DC must be considered cautiously. A clear dialogue between physicians and patient caregivers is needed to outline the absence of definitive clinical data on functional outcomes in patients after this procedure. The true effect of DC on neurological outcomes or death after aSAH remains to be determined. Conclusive evidence for possible predictors of outcome after DC, such as young age, early timing, and hematoma volume or location, might also inform clinical decision making.
guidelines for Future research
The effect of DC on functional outcome after stroke and TBI was seen initially in prospective registries and cohorts. 16, 38 The research and treatment protocols for these pathologies have changed considerably to allocate patients who would benefit from surgical intervention. For example, it was thought initially that high ICP readings would guide DC for large infarctions, but in a well-designed prospective evaluation, this measurement was not found to be useful in directing treatment of increased ICP in patients after stroke. 37 Thus, additional prospective studies are needed first to delineate the role of DC in aSAH and to guide the design of randomized controlled trials, which are the gold standard in this setting. They are are needed to systematically compare the efficacy of nonsurgical therapy and DC in patients with aSAH. A more meaningful analysis of outcomes will require future studies aimed at developing well-defined protocols for categorizing the indications and timing of DC.
Conclusions
This study summarizes the best available evidence for DC in the treatment of poor-grade aSAH. DC is associated with high unfavorable outcome and mortality rates. However, our findings are consistent with those of other studies in the literature and suggest that earlier DC could lead to better outcomes than late DC. The exact role of DC in improving survival and clinical outcomes over nonsurgical interventions is unknown because of the lack of control groups and limited existing data, most of which are retrospective in nature. A prospective randomized study is warranted to provide more conclusive evidence for the role of DC in patients with poor-grade aSAH. 
